Nature Communications (May 2021)
A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes
- Yu Guo,
- Lisu Huang,
- Guangshun Zhang,
- Yanfeng Yao,
- He Zhou,
- Shu Shen,
- Bingqing Shen,
- Bo Li,
- Xin Li,
- Qian Zhang,
- Mingjie Chen,
- Da Chen,
- Jia Wu,
- Dan Fu,
- Xinxin Zeng,
- Mingfang Feng,
- Chunjiang Pi,
- Yuan Wang,
- Xingdong Zhou,
- Minmin Lu,
- Yarong Li,
- Yaohui Fang,
- Yun-Yueh Lu,
- Xue Hu,
- Shanshan Wang,
- Wanju Zhang,
- Ge Gao,
- Francisco Adrian,
- Qisheng Wang,
- Feng Yu,
- Yun Peng,
- Alexander G. Gabibov,
- Juan Min,
- Yuhui Wang,
- Heyu Huang,
- Alexey Stepanov,
- Wei Zhang,
- Yan Cai,
- Junwei Liu,
- Zhiming Yuan,
- Chen Zhang,
- Zhiyong Lou,
- Fei Deng,
- Hongkai Zhang,
- Chao Shan,
- Liang Schweizer,
- Kun Sun,
- Zihe Rao
Affiliations
- Yu Guo
- State Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University
- Lisu Huang
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- Guangshun Zhang
- State Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University
- Yanfeng Yao
- Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences
- He Zhou
- HiFiBio (Hong Kong) Limited
- Shu Shen
- State Key Laboratory of Virology and National Virus Resource Center, Wuhan Institute of Virology, Chinese Academy of Sciences
- Bingqing Shen
- HiFiBio (Hong Kong) Limited
- Bo Li
- State Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University
- Xin Li
- State Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University
- Qian Zhang
- HiFiBio (Hong Kong) Limited
- Mingjie Chen
- HiFiBio (Hong Kong) Limited
- Da Chen
- State Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University
- Jia Wu
- HiFiBio (Hong Kong) Limited
- Dan Fu
- State Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University
- Xinxin Zeng
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- Mingfang Feng
- HiFiBio (Hong Kong) Limited
- Chunjiang Pi
- HiFiBio (Hong Kong) Limited
- Yuan Wang
- State Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University
- Xingdong Zhou
- State Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University
- Minmin Lu
- HiFiBio (Hong Kong) Limited
- Yarong Li
- Wuxi Biologics Limited
- Yaohui Fang
- State Key Laboratory of Virology and National Virus Resource Center, Wuhan Institute of Virology, Chinese Academy of Sciences
- Yun-Yueh Lu
- HiFiBio (Hong Kong) Limited
- Xue Hu
- State Key Laboratory of Virology and National Virus Resource Center, Wuhan Institute of Virology, Chinese Academy of Sciences
- Shanshan Wang
- HiFiBio (Hong Kong) Limited
- Wanju Zhang
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- Ge Gao
- Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences
- Francisco Adrian
- HiFiBio (Hong Kong) Limited
- Qisheng Wang
- Shanghai Synchrotron Radiation Facility, Shanghai Advanced Research Institute, Chinese Academy of Sciences
- Feng Yu
- Shanghai Synchrotron Radiation Facility, Shanghai Advanced Research Institute, Chinese Academy of Sciences
- Yun Peng
- Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences
- Alexander G. Gabibov
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences
- Juan Min
- Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences
- Yuhui Wang
- State Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University
- Heyu Huang
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- Alexey Stepanov
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences
- Wei Zhang
- State Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University
- Yan Cai
- Tianjin International Joint Academy of Biotechnology & Medicine
- Junwei Liu
- Tianjin International Joint Academy of Biotechnology & Medicine
- Zhiming Yuan
- Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences
- Chen Zhang
- State Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University
- Zhiyong Lou
- MOE Key Laboratory of Protein Science & Collaborative Innovation Center of Biotherapy, School of Medicine, Tsinghua University
- Fei Deng
- State Key Laboratory of Virology and National Virus Resource Center, Wuhan Institute of Virology, Chinese Academy of Sciences
- Hongkai Zhang
- State Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University
- Chao Shan
- State Key Laboratory of Virology and National Virus Resource Center, Wuhan Institute of Virology, Chinese Academy of Sciences
- Liang Schweizer
- HiFiBio (Hong Kong) Limited
- Kun Sun
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- Zihe Rao
- State Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University
- DOI
- https://doi.org/10.1038/s41467-021-22926-2
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 11
Abstract
Antibodies against SARS-CoV-2 S protein can provide a treatment strategy for COVID-19. Here, Guo et al. provide the crystal structure of a SARS-CoV2 neutralizing antibody isolated from a convalescent patient and highlight the therapeutic efficacy in a rhesus monkey model of an engineered version with optimized pharmacokinetic and safety profile.
